The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease

Genetics in Medicine

Volumn 13, Issue 8, 2011, Pages 729-736

  Banugaria, Suhrad G ^a   Prater, Sean N ^a   Ng, Yiu Ki ^b   Kobori, Joyce A ^c   Finkel, Richard S ^d   Ladda, Roger L ^e   Chen, Yuan Tsong ^f   Rosenberg, Amy S ^g   Kishnani, Priya S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^f INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

CRIM negative; crossreactive immunologic material; enzyme replacement therapy; high sustained antibody titers; high titer CRIM positive; low titer CRIM positive; Pompe disease; therapeutic proteins

Indexed keywords

BIOLOGICAL MARKER; ENZYME ANTIBODY; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCAN 1,4 ALPHA GLUCOSIDASE ANTIBODY; GLUCOSE TETRASACCHARIDE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; TETRASACCHARIDE; UNCLASSIFIED DRUG;

ALBERTA INFANT MOTOR SCALE; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DISEASE COURSE; ENZYME REPLACEMENT; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HUMAN; INFANT; MALE; MOTOR DEVELOPMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; RATING SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALPHA-GLUCOSIDASES; ANTIBODIES; ANTIBODIES, NEUTRALIZING; BIOLOGICAL MARKERS; DEVELOPMENTAL DISABILITIES; ENZYME ASSAYS; ENZYME REPLACEMENT THERAPY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HEART VENTRICLES; HEXOSES; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MALE; ORGAN SIZE;

EID: 80051799963     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3182174703     Document Type: Article

References (37)

1. Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency [Internet Resource; Computer File Date of Entry:20090331]. New York: McGraw-Hill, 2009. Available at: http://genetics.accessmedicine.com/.
2. Hug G. Pre-and postnatal pathology, enzyme treatment, and unresolved issues in five lysosomal disorders. Pharmacol Rev 1978;30:565-591. (Pubitemid 10186587)
3. van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease:20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-340. (Pubitemid 36951395)
4. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671-676.
5. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68:99-109. (Pubitemid 46071892)
6. Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009;11:210-219.
7. Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009;66:329-335.
8. Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 2006;149:89-97. (Pubitemid 44081924)
9. Hawes ML, Kennedy W, O'Callaghan MW, Thurberg BL. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease. Mol Genet Metab 2007;91:343-351. (Pubitemid 47043513)
10. Raben N, Takikita S, Pittis MG, et al. Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand. Autophagy 2007;3:546-552. (Pubitemid 350060050)
11. Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010;99:26-33.
12. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-138.
13. Piper M, Darrah J. Motor assessment of the developing infant. Philadelphia: WB Saunders Co., 1994.
14. Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005;15:24-31. (Pubitemid 41556629)
15. An Y, Young SP, Hillman SL, Van Hove JL, Chen YT, Millington DS. Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease. Anal Biochem 2000;287:136-143.
16. Young SP, Stevens RD, An Y, Chen YT, Millington DS. Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilutionelectrospray ionization tandem mass spectrometry. Anal Biochem 2003;316:175-180. (Pubitemid 36444547)
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
18. Vogel M, Staller W, Buhlmeyer K. Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children. Pediatr Cardiol 1991;12:143-149.
19. Turner CT, Hopwood JJ, Brooks DA. Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats. Mol Genet Metab 2000;69:277-285. (Pubitemid 30333662)
20. Raben N, Nagaraju K, Lee A, et al. Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice. Transgenic Res 2003;12:171-178. (Pubitemid 36573230)
21. Sun B, Bird A, Young SP, Kishnani PS, Chen YT, Koeberl DD. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet 2007;81:1042-1049. (Pubitemid 47580255)
22. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med 2009;360:194-195.
23. Richards SM. Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders. Clin Appl Immunol Rev 2002;2:241-253. (Pubitemid 35439108)
24. Porter S. Human immune response to recombinant human proteins. J Pharm Sci 2001;90:1-11. (Pubitemid 32050471)
25. Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 2008;94:319-325.
26. Hollak CE, Linthorst GE. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome? Mol Genet Metab 2009;96:1-3.
27. Richards SM, Olson TA, McPherson JM. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 1993;82:1402-1409. (Pubitemid 23263954)
28. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-188. (Pubitemid 32064139)
29. van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010;362:1396-1406.
30. de Vries JM, van der Beek NA, Kroos MA, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 2010;101:338-345.
31. Dickson P, Peinovich M, McEntee M, et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest 2008;118:2868-2876.
32. Rodriguez NI, Hoots WK. Advances in hemophilia: experimental aspects and therapy. Pediatr Clin North Am 2008;55:357-376, viii. (Pubitemid 351442785)
33. Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant 2002;17(suppl 5):42-47. (Pubitemid 34823072)
34. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998;50:1266-1272. (Pubitemid 28240338)
35. Marshall MO, Heding LG, Villumsen J, et al. Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. Diabetes Res 1988;9:169-175. (Pubitemid 19105417)
36. Rougeot C, Marchand P, Dray F, et al. Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children. Horm Res 1991;35:76-81.
37. Kempton CL, White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009;113:11-17.